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1. Abbreviations 
FEV1  Forced expiratory volume in first second 
PEF  Peak expiratory flow 
FVC  Forced vital capacity 
FEF50  Forced expiratory flow at 50% of FVC expired 
FEF75  Forced expiratory flow at 75% of FVC expired 
TLC  Total lung capacity 
FRC  Functional residual capacity 
RV  Residual lung volume 
Raw  Airway resistance 
PD20  Provocative dose of methacholine causing a 20% reduction in FEV1  
VLBW  Very low birth weight, i.e. < 1500 grams 
ELBW  Extremely low birth weight, i.e. < 1000 grams 
PMA  Post menstrual age, i.e. the age in weeks since conception 
GA  Gestational age, i.e. the age in weeks since conception 
BW  Birth weight 
RDS  Neonatal respiratory distress syndrome 
BPD  Bronchopulmonary dysplasia 
CLD  Chronic lung disease of prematurity 
PDA  Persistent ductus arteriosus 
A preterm A subject born at a PMA ≤ 28 weeks or with a BW ≤ 1000 grams 
NICU  Neonatal intensive care unit 
AHR   Airway hyperresponsiveness 
mSv  Milli Sievert 
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2. Abstract 
Background: Survival after extremely premature birth has increased over the past decades, 
parallel to advances in perinatal and neonatal care. As more vulnerable infants survive, the 
incidence of bronchopulmonary dysplasia (BPD) has increased. Currently, BPD has been 
proposed the most common chronic lung disease in infancy. Subsequent to premature birth 
and neonatal BPD, there are reports of clinical asthma, airway obstruction, airway 
hyperresponsiveness (AHR), pulmonary hyperinflation and radiological findings in 
schoolchildren, adolescents and selected samples of adults. There is little population-based 
knowledge on these issues in young adults who were born prematurely in the early era of 
neonatal intensive care medicine. Furthermore, outcome in these pioneer subjects has not 
been compared to outcome in comparable survivors of more recent neonatal intensive care. 
While inflammation is important in neonatal BPD, there is limited knowledge on the 
mechanisms underlying later respiratory manifestations. Principal determinants for long-term 
pulmonary sequelae are not well established. Most knowledge relating to lung sequelae from 
premature birth is based on samples of subjects defined by their birthweight and born at 
tertiary level teaching hospitals. Finally, the feasibility of lung function testing has not been 
examined in this population. 
Aims: In population-based cohorts of long-term survivors from extremely premature birth: 
• To assess the feasibility and precision of lung function testing.  
• To assess pulmonary outcome in young adults born in the early 1980’s. 
• To compare pulmonary outcome in subjects born in the early 1980’s and in the early 
1990’s. 
• To assess the relevance and importance of the following variables for asthma, airway 
obstruction and AHR: Inheritance, allergy, selected markers of airway inflammation, 
exposures to cigarette smoking and various conditions in the neonatal period. 
• To establish knowledge regarding pulmonary radiological findings. 
Design: Population-based, controlled, historical, prospective cohort study. 
Subjects: Preterms consisted of two population-based cohorts of subjects with gestational age 
≤ 28 weeks or birthweight ≤ 1000 grams, born consecutively within the study region in 
western Norway in the years 1982-85 (first birth-cohort) and 1991-1992 (second birth-
cohort). For each preterm, the temporally closest term-born and willing subject of the same 
gender with birthweight between 3.0 and 4.0 kilograms was recruited as control.  
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Study setting and methods: Subjects were examined twice within two weeks in 2001/2002 
at the paediatric Cardio-Pulmonary Laboratory at Haukeland University Hospital with 
standard equipment and in accordance with international guidelines. Airflow obstruction was 
assessed from maximum flow volume loops, lung volumes with whole body 
plethysmography, airway hyperresponsiveness (AHR) with methacholine provocation and 
bronchial lability with tests for exercise induced asthma and reversibility to salbutamol. 
Allergy was assessed with skin prick tests. Airway inflammation was assessed by measuring 
urinary leukotriene E4, urinary eosinophilic protein X, serum eosinophilic cationic protein and 
whole blood counts of eosinophilic granulocytes. Radiological imaging of the lungs was done 
with high resolution CT technique (HRCT). Respiratory symptoms and relevant background 
information was established with questionnaires and a standardised interview by a 
paediatrician.     
Results: Spirometry and whole body plethysmography are precise and feasible methods for 
assessment of airway function and lung volumes in subjects born preterm. Young adults born 
preterm in the early 1980’s had more asthma and significant airway obstruction, AHR and 
pulmonary hyperinflation, compared to control subjects born at term. The incidences of BPD 
among preterms born in the early 1980’s and in the early 1990’s were similar. Compared to 
matched controls, current airway obstruction, AHR and pulmonary hyperinflation were 
similarly increased in the two preterm cohorts. Furthermore, current deficits in important lung 
function variables were similarly associated with the severity of neonatal respiratory disease 
in both cohorts. Compared to matched controls, current FEV1 was reduced with respectively 
18.6% and 18.7% of predicted in the two birth-cohorts in preterms who required supplemental 
oxygen at 36 weeks postmenstrual age. One-hundred days with neonatal oxygen treatment 
predicted decreases in current FEV1 of 12% and in current FEF50 of 25%, and these figures 
were similar in both birth-cohorts. With respect to subsequent small airway obstruction, the 
influence from a neonatal diagnosis of BPD seemed to have increased in the most recent 
birth-cohort. In preterms, the occurrence of asthma and AHR was unrelated to inheritance, 
allergy, markers of eosinophilic airway inflammation and cigarette exposures. AHR was 
instead strongly related to prolonged neonatal requirement for oxygen treatment. Radiological 
findings were observed in 63 (88%) of the subjects undergoing CT scanning of the lungs. 
Most of the described pathology seemed relatively minor, such as discrete linear or triangular 
opacities of unknown prognostic significance. There was significantly less findings in the 
second birth cohort.  
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Concluding remarks and implications: Pulmonary sequelae after extremely premature birth 
were demonstrated throughout childhood and into early adult life. In the two birth-cohorts, 
adverse outcome was strongly and similarly related to neonatal respiratory morbidity, and to 
prolonged requirements for oxygen treatment. Asthma and AHR in preterms were unrelated to 
the assessed markers of airway inflammation and to features usually observed with asthma. 
These findings suggest irreversible, structural damage to the airways and/or to the pulmonary 
interstitium as causal factors, rather than an ongoing, active inflammatory disease. Less 
radiological findings in the second birth-cohort may reflect less structural damage in preterms 
born in the 1990’s. Survival in infants born after short gestation is still associated with long 
requirements for oxygen treatment. Providing that adverse pulmonary outcome is still linked 
to prolonged neonatal oxygen exposure, current BPD-survivors may be developing similar 
lung injury. Relatively minor pulmonary insults in early childhood have been associated with 
chronic obstructive pulmonary disease (COPD) in adults. There is now evidence to indicate 
that subsets of young people with a neonatal history of BPD may become future COPD 
patients. Furthermore, there is reason to speculate that contemporary BPD-survivors may 
develop similarly. 
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4. Background information 
4.1 The epidemiology of premature birth 
Premature birth is related to low birthweight and vice versa. Birthweight is a readily available 
and reliable figure, and therefore often used as a substitute for gestational age to define 
samples and incidences. In research aiming to describe consequences of premature birth, this 
strategy may introduce inaccuracies due to inclusion of infants that are small for gestational 
age and therefore more mature than expected from their birthweight. Antenatal organ 
development is an orderly process governed by genetic information and complex cellular 
interactions that are related to the fetal stage of development. Impact from premature birth on 
the normal schedule of pulmonary development thus seems better described through 
assessment of subjects included on the basis of postmenstrual age (PMA) at birth, rather than 
birthweight. Few long-term follow-up studies have taken this position in the process of 
subject inclusion. Therefore, current understanding of long-term consequences from 
premature birth is to a large extent derived from knowledge based on very low birthweight 
(VLBW) infants. Since gestational age at birth is critical for lung development and also 
important for the immediate decision to initiate life support at birth, this is not an optimal 
situation. 
4.1.1 Survival data 
The overall incidence of premature delivery has been fairly constant in Norway over the last 
decades, in the range of 1.3-1.5 VLBW infant per 100 births (1). However, premature infants 
born today face a considerably better chance of survival than comparable infants born in the 
second half of the last century. Perinatal and neonatal mortality rates have declined for all 
weight classes since the 1960’s (1;2). The reasons for this have been manifold, but for VLBW 
infants, changes have coincided with the introduction of assisted ventilation and the 
development of neonatal intensive care medicine. From the 1960’s to the 1980’s, the chances 
of survival for live born VLBW infants trebled, and for the smallest infants weighing between 
751 and 1000 grams, survival improved from nearly zero to 42-75% (3). In the 1990’s, 
development in perinatology and neonatal intensive care medicine was paralleled by further 
improvements in the survival rates, particularly for the most immature infants (4;5). The 
Neonatal Research Network reported that survival to discharge was 74%, 80% and 84% for 
VLBW infants born in the years 1988, 1991 and 1995-96, respectively (6). In the second half 
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of the 1990’s, further improvements were noted (7). In Norway in the two years 1999 and 
2000, 636 infants were born at PMA < 28 weeks or with birthweight < 1000 g. Of these, 462 
(73%) were considered viable and admitted to a NICU (8). Altogether 376 infants survived to 
discharge, which is 59% of all included infants or 81% of those who were admitted to a 
NICU.  
 
There are wide variations as to reported outcomes (9). Allen et al. (10) reported survival rates 
of up to 80% for infants born at 25 weeks’ gestation in the early 1990’s, while others reported 
considerably lower survival rates (5). For infants with birthweight less than 750 grams, 
survival ranged from 32% to 46% (11). 
 
   
 
These variations reflect several factors. First, there may be real differences in treatment 
qualities and policies. Second, the study populations are not necessarily comparable, i.e. some 
are recruited from single tertiary centres and others from geographically defined areas (5). 
The denominator may be the total number of deliveries or only those infants considered viable 
and admitted to NICU care. When survival is estimated according to gestational age at birth, 
the quality of the pregnancy data is crucial. Furthermore, perinatal practice and mortality are 
influenced by the attitude and the ability of the neonatologists to salvage immature infants at 
the edge of viability. These matters may also induce changes with respect to classification of 
perinatal mortality: Extremely vulnerable infants may increasingly have been classified as live 
births rather than spontaneous abortions or stillbirths (12).  
4.1.2 Development of neonatal intensive care 
Modern intensive care neonatology commenced with the introduction of mechanical 
ventilation in the 1960’s. In Bergen, mechanical ventilation of a premature infant was first 
done in 1969 (Gjermund Fluge, personal communication). In the following 35 years, there 
Neonatal survival according to gestational 
age at birth in two periods. 
From Tin, Waryiar and Hey, 
BMJ 1997.
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have been vast improvements in antenatal, perinatal and neonatal care of premature babies. 
Better technologies and treatment procedures relating to assisted ventilation were fundamental 
elements in this development. Better techniques for non-invasive surveillance of blood gases 
and oxygen tension (13) facilitated more exact administration of ventilatory support and 
oxygen therapy. Continuous arterial blood pressure surveillance and arterial blood sampling 
became a safe procedure through better equipment for access to peripheral arteries. The 
importance of adequate nutrition was gradually recognized (14-17), and intravenous nutrition 
was facilitated by techniques for central venous access through peripheral veins (18). 
Treatment of persistent ductus arteriosus (PDA) with surgery or indomethacin became more 
aggressive as the impact on respiratory distress syndrome (RDS) from over-hydration (19;20) 
and over-perfusion of the lung (21;22) became evident. More aggressive use of antibiotics 
(23) and a better understanding of aspects relating to the prevention of neonatal septicaemia 
have  been important, as have better nursing procedures (24). Antenatal corticosteroids was 
gradually introduced in clinical medicine in the 1980’s and early 1990’s, reducing perinatal 
mortality, respiratory distress syndrome and intraventricular haemorrhage (25;26). Beneficial 
effects from postnatal corticosteroids on RDS was demonstrated in the early 1980’s (27;28). 
In the late 1990’s, however, awareness of long-term negative neurological effects (29) limited 
its use, despite documented positive effects on respiratory morbidity (30-33). Surfactant 
replacement therapy was introduced in clinical routines in the late 1980’s and early 1990’s, 
and had significant impact on acute respiratory morbidity and death rates from RDS (34;35). 
The importance of standardisation of complex neonatal intensive care schemes together with 
coordinated and multidisciplinary programs for research, education and quality improvements 
on all levels, was expressed internationally through the Vermont Oxford Network, established 
in 1989 in the USA (36;37).  
 
Collectively, these changes have increased perinatal survival, reduced acute neonatal 
morbidity and increased neonatal survival after premature birth, particularly in the most 
immature. Thus, more premature infants have been exposed to neonatal intensive care, and 
more of them have survived. The first large birth-cohorts of these young individuals have only 
recently started to reach adulthood. Population based knowledge on their long-term 
pulmonary outcome is virtually non-existent. Since the total number of low-birthweight 
deliveries remains relatively stable and the survival rates increase, the number of preterms 
discharged alive is increasing. Chronic neonatal pulmonary morbidity - bronchopulmonary 
dysplasia (BPD) - has not decreased and may in fact be increasing (4;35;38;39). Measures that 
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are beneficial for survival and acute neonatal morbidity may not necessarily be beneficial in 
relation to long-term morbidity. Effects from these evolving changes with respect to long-
term respiratory health are poorly described in the literature. 
4.2 Chronic neonatal pulmonary morbidity 
Pulmonary sequelae after neonatal respiratory distress syndrome were initially described by 
Shepard and Robertson in the 1960’s. In 1967, Northway et al. (40) coined the term 
"Bronchopulmonary Dysplasia” (BPD) to describe a constellation of clinical, radiological and 
pathologic findings in oxygen treated, ventilated premature infants. Since then, the 
characteristics of infants requiring long-term ventilatory support have changed, as have 
definitions of BPD. In the literature, the term has come to signify a need for supplementary 
oxygen at various ages, sometimes in combination with abnormal radiological findings. In 
1979, Tooley et al. (20) suggested a cut off point of 30 days of oxygen supplementation to 
define BPD. In 1988, Shennan et al. (41) reported that oxygen requirements at 36 weeks PMA 
was a better predictor of abnormal pulmonary outcome the first two years of life and 
introduced the term Chronic Lung Disease of Prematurity (CLD). In 2001, an attempt to 
categorize the severity of BPD was put forward in a NICHD/NHLBI/ORD work shop 
summary in Bethesda, USA, by Jobe and Bancalari (39). Infants born before 32 weeks PMA 
requiring supplemental oxygen for at least 28 days were classified as mild BPD if they were 
breathing room air at 36 weeks PMA. Requirement for supplemental oxygen < 30% at 36 
weeks PMA was defined as moderate BPD whereas requirements ≥ 30% was defined as 
severe BPD. 
 
Different definitions of BPD and CLD have been used in different studies. As discussed by 
Bancalari (42), BPD has been defined by the total number of postnatal days (28 days) with 
requirement for supplemental oxygen, by the postnatal age (28 days) at which weaning from 
supplemental oxygen is possible or by the post menstrual age (36 weeks) at which weaning 
from supplemental oxygen is possible. Defining BPD by oxygen treatment at 36 weeks PMA 
tends to equalize its incidence across gestational ages, as an immature infant of 24 weeks will 
require much longer duration of oxygen supplementation than a more mature infant to reach 
that criterion. As oxygen is used both to define and to treat neonatal lung disease, further 
methodological problems appear. There are few generally agreed upon criteria for 
discontinuation of oxygen therapy. In a single institution, one can assume that infants in 
oxygen at a particular postnatal or postmenstrual age have worse lung disease than those in 
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room air. However, it does not follow that infants in oxygen at one institution are similar to 
infants in oxygen at another. Conclusions from multi-centre studies may therefore be blurred. 
4.3 The epidemiology of neonatal Bronchopulmonary Dysplasia 
The reported incidences of BPD vary widely, cross-sectionally as well as longitudinally, and 
several factors contribute to this variation. Firstly, real differences with respect to patient 
management (43) and strategies for weaning from oxygen treatment (44) are important. 
Secondly, the nature of the studied preterm populations varies. With increasing survival of 
immature infants, the population at risk of developing BPD increases (38). The rates of BPD 
will therefore vary according to the constitution of the population studied. Thus, results will 
be influenced by the time period of the study. For the same reason, hospital based studies may 
produce results that differ from area based studies. Thirdly, the base population from which 
incidence is calculated varies. The denominator may be all infants born prematurely, only 
surviving premature infants, only infants admitted to a NICU, only infants within certain 
categories of birthweight or gestational age, only ventilated infants or only so called “at-risk 
infants” etc. Lastly, differences relating to which infants are labelled and defined as suffering 
from BPD obviously must influence its incidence (42).  
 
These inconsistencies regarding fundamental medical and epidemiological criteria used to 
identify BPD may disguise causal factors and seriously hamper the search for causal pathways 
as well as the understanding of its long-term outcome. Standard diagnostic criteria are critical 
for rational interpretations of clinical studies using BPD as an outcome or explanatory 
variable, and for comparisons between them.  
 
In the late 1970’s, the reported incidence of BPD in infants mechanically ventilated for RDS 
ranged from 10-20% (19;45;46). Besides differences with respect to patient populations or 
management, differences were explained by inconsistent definitions (22). For infants with 
birthweight between 700-1500 g treated at eight major NICU’s in the USA in 1982-1984, 
significant and substantial differences in the incidence of infants requiring prolonged oxygen 
supplementation were observed (43). These differences incited discussions still unresolved, 
relating to strategies for assisted ventilation (47). In the mid 1990’s the incidence of BPD 
defined as oxygen dependency at 36 weeks PMA in infants with birth weight 501-1500g, 
ranged from 3% to 43% in the 14 different participating centres of the National Institute of 
Child Health and Human Development (NICHD) Neonatal Network (6). Overall incidence 
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increased from 19% in 1991 to 23 % in 1996. Bancalari et al. have reported incidences of 
BPD from the same institution in 1986 and in 2003 (22;42): In 1986, in infants who had been 
mechanically ventilated and survived to 28 days, incidence ranged from 85% for those 
weighing below 700 g, to 16% in the 1000-1300 g group and 5% in those weighing more than 
1300. In 2003, incidence ranged from 67% in the 500-750 g group to less than 1% in the 
1251-1500 g group. Young et al. (4) compared rates of chronic lung disease in VLBW infants 
in North Carolina in 1984 (48) and 1994. An “at risk-group” was defined as infants ventilated 
> 48 hours. In 1984, the proportion requiring ventilation or supplemental oxygen at 30 days 
was 54% and in 1994 it was 68%, a significant increase. Data from Palta et al., suggest an 
increase in CLD from the pre-surfactant to the post-surfactant era, and survival without CLD 
morbidity did not change (49). In the EPICure study, focusing on infants born before 26 
completed weeks PMA, 74% were still receiving supplemental oxygen at 36 weeks PMA, as 
were 51% at term (50). In a Swedish study of infants with birth weight < 1000g, 28% were 
dependent on oxygen supplementation at 36 weeks PMA (51). Among infants born at PMA < 
28 weeks or with birthweight < 1000 grams in Norway in 1999 and 2000, 123 (33%) of 376 
survivors still required treatment with supplemental oxygen at 36 weeks PMA (8). 
 
In conclusion, the epidemiology of BPD is difficult to interpret for reasons relating to 
inconsistent definitions and varying population characteristics. Clinically, the severity of the 
condition seems to decrease while long periods of oxygen supplementation continue to be 
required, particularly to salvage the smaller infants. Increased survival in the lowest weight 
classes and among the most immature infants thus seems to occur at a cost of increased 
chronic neonatal pulmonary morbidity. The long-term consequences are largely unknown. 
4.4 The aetiology of Bronchopulmonary Dysplasia 
The aetiology of a clinical condition characterized by “prolonged need for oxygen 
supplementation” must be multifactorial, i.e. BPD is not a clearly defined disease-entity with 
a static set of explanatory and prognostic variables, but rather a syndrome with a common 
denominator being prolonged requirement for supplemental oxygen. Why BPD develops in 
some premature infants and not in others, is still not well understood.  
 
In a preterm infant, lung development that normally should take place in utero, instead must 
occur after birth while the lungs function as a gas exchanging organ. Instead of quiet 
“breathing” of amniotic fluid, the immature lung tissue is mechanically inflated by a gas 
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mixture with considerably higher oxygen tension, paralleled by stretch and relaxation inflicted 
by mechanical ventilation (52). Furthermore, at birth the fetal lung is exposed to a series of 
fundamental physiological changes, such as perfusion with a full cardiac output with 
considerable higher oxygen tension than during fetal life (42), nutritional alterations (15), and 
exposure to infections (53), inflammation (54), oxidative stress (55) and proteolytic enzymes 
(56). 
 
Clearly, the main risk factor for both RDS and BPD is the extent of prematurity (39). Lung 
development evolves through genetically scheduled phases, starting with an embryonic phase 
(the first 7 weeks) which is followed by a pseudoglandular (7 to 16 weeks), canalicular (16 to 
26-28 weeks) and saccular (26-28 to 32-36 weeks) phase and ends with the alveolar phase, 
starting at 32-36 weeks and ending at approximately 18 months of postnatal age (57;58). In an 
infant born prematurely, this developmental process is disturbed and probably interrupted by 
mechanical ventilation, hyperoxia, left to right shunting through a PDA, altered nutrition, 
oxidative stress, inflammation, infections and proteolytic enzymes (39). The ability of an 
immature infant to handle factors such as oxidative, inflammatory and proteolytic stress, may 
be reduced and may also conceivably vary between individuals (59). It is important to bear in 
mind that the mere exposure to room air represents hyperoxia relative to intrauterine 
conditions. The relative importance of the different factors involved, remains to be defined, 
and multiple pathways to injury seem plausible. Better treatment of RDS and acute neonatal 
morbidity have facilitated survival of more infants born in the canalicular stage and before 
formation of terminal acini. The pathology and clinical expression of BPD therefore have 
changed (58), as have probably also its dominating causes. 
 
The factors causing premature delivery vary, and at birth each neonate already has an 
individual medical history. The effects from postnatal events, conditions and therapeutic 
interventions are modulated by the previous antenatal history of the babies (60-62), their 
genetic constitution (63), possibly by gender (64-66) and by the PMA at which they are born 
(39). The subsequent treatment modalities and policies these infants are exposed to, have 
changed over time, and also vary cross-sectionally between countries and hospitals. As 
survival rates increase, the number infants at risk of developing BPD increase. Due to this 
heterogeneity of the preterm population and the imprecise definition of BPD, the search for 
one particular causal factor or sequence of events, seems a difficult exercise. 
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A fundamental question is whether prematurity per se is compatible with normal lung 
development and growth, and what benefits can be expected from further improvements in 
treatment schemes and modalities (67). Hjalmarson et al. studied healthy preterm and full-
term infants at the same PMA of 40 weeks, and concluded that preterm birth per se changed 
the normal development of lung function (68). In a follow up study, they concluded that 
ventilatory impairments were also influenced by the extent of neonatal BPD (69). 
Impairments following BPD were of the same nature as in healthy preterm infants, but the 
magnitude was related to the clinical severity of BPD. Loss of bronchial function in the first 
year of life has been reported in premature infants, irrespective of  the treatment modalities 
used, and also in children without apparent neonatal respiratory disease (70-72). Hofhuis et al. 
(70) found a possible beneficial effect from high-frequency oscillation, whereas a recent 
report from The United Kingdom Oscillation Study, questioned this (73). These data suggest 
that reduced lung and airway function following preterm birth may be related to 
developmental changes caused by the premature birth per se as much as to the initial disease 
severity or treatment effects (72). Because airway development precedes development of the 
acini and the pulmonary microvasculature, parenchymal development may be more disturbed 
by premature birth than airway abnormalities. However, assessment of potential parenchymal 
injury and of acinar structure and function is hampered by the lack of readily available non-
invasive techniques.  
In conclusion, in the development of BPD, the relative contributions from prematurity per se 
versus potentially harmful exposures, events or treatments are difficult to discern, and may 
vary between individuals according to their genetic predispositions, antenatal history and 
PMA at birth. Insight in theses matters may only be gained through long-term physiological 
follow-up studies of population based cohorts of preterms handled according to standardised 
schemes and definitions. 
4.5 The pathology of neonatal Bronchopulmonary Dysplasia 
As exogenous surfactant and advances in neonatal critical care medicine have led to less 
barotrauma and oxygen injury, the pathology of BPD has changed. These changes have been 
expressed through the concepts “old” and “new” BPD (58). 
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4.5.1 “Old” Bronchopulmonary Dysplasia 
As reviewed by Coalson (74), pathological changes primarily consisted of severe airway 
injury and alternating sites of pulmonary overinflation and fibrosis/atelectasis. There were 
squamous metaplasia and hyperplasia of the airway epithelium, bronchial and bronchiolar 
mucosal metaplasia, peribronchiolar smooth muscle hypertrophy and interstitial fibrosis. 
Cardio-vascular lesions consisted of periarteriolar thickening, right ventricular hypertrophy 
and cardiomegaly with cor pulmonale in the severe cases. Pathological changes were evoked 
by hyperoxia and ventilator induced injury on a relative immature and surfactant deficient 
lung. 
4.5.2 “New” Bronchopulmonary Dysplasia 
During the 1980’s, autopsy studies described a “tubular alveolar structure”, reduced alveolar 
numbers and reduced internal surface area measurements (75), suggesting reduced postnatal 
alveolar growth. Alveolar hypoplasia with enlarged, simplified airspaces, variable amounts of 
fibrosis of the alveolar interstitial septae and dysmorphic vascular changes have later been 
consistent findings in BPD autopsies. Impaired alveolar growth and developmental arrest are 
hallmarks of “new BPD”. A reduced surface area for gas exchange and a decrease in the size 
and complexity of the pulmonary capillary bed are physiological consequences. At 24 weeks 
PMA, the lung is in its canalicular stage of development and at 30 weeks still not in the 
alveolar stage. Thus, premature birth and the initiation of pulmonary gas exchange interrupts 
normal septation and acinar development. During fetal development, the lung exists in a 
relatively hypoxic environment, and therefore air itself represents hyperoxia. Studies have 
shown that exogenous surfactant alone does not enhance alveolarisation in BPD-survivors 
(76;77). In premature baboons, alveolar hypoplasia and vascular developmental arrest were 
present, despite antenatal steroids and postnatal surfactant replacement (58). The dominant 
lesions in animal models (77;78) and in humans after modern treatment regimens, are delayed 
development of the acinus of the lung with abnormal alveolarisation, altered elastic and 
collagen tissue networks and disturbed vascularisation (52;58;76;79). Lung mechanics may be 
affected by the described abnormalities. Enlarged airspaces can result in hyperinflation. 
Furthermore, alveolar wall and parenchymal attachments are structures through which lung 
recoil exerts its force on small airways to prevent airway closure during exhalation (80). 
Altered elastic recoil will lead to abnormally low expiratory flow rates (81). Concluding her 
chapter on the pathology of BPD in a recently published book (74), Coalson expresses her 
worries that BPD in current extremely low birth weight survivors, may have as serious long-
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term consequences in adulthood as in those infants who acquired BPD in the 1960’s. Similar 
concerns are expressed by Hack and Fanaroff (11). To gain knowledge on these issues, 
premature infants should continually be followed up into adulthood and results compared to 
previous data. 
 
4.5.3 Pathophysiology of Bronchopulmonary Dysplasia 
The early stages of BPD are almost invariably characterized by an intense acute inflammatory 
response followed by chronic inflammation and airway remodelling (39;82). There is 
furthermore evidence that antenatal inflammatory mechanisms may influence the occurrence 
of neonatal BPD (60;62;83). Beyond infancy, the pathophysiology of BPD is poorly 
described. While an eosinophil-driven inflammatory process is central in asthma (84), we 
know little about the nature and relevance of airway inflammation in long-term BPD 
survivors. Airway pathology of BPD beyond infancy has not been properly investigated, and 
to my knowledge, no studies exist on bronchoalveolar lavage fluid or bronchial biopsies. 
Recently, Baraldi et al. (85) described low levels of exhaled nitric oxide (eNO) in school aged 
BPD survivors compared to FEV1-matched asthmatic children. This underscores the 
differences between these two types of paediatric obstructive lung disease. However, due to a 
similar clinical presentation, asthma medication is frequently prescribed (86-88), despite few 
studies documenting effect (89). A better understanding of the causal mechanisms for airway 
pathology in BPD survivors is fundamental for adequate treatment. Due to a clinical 
resemblance with classical asthma, it is particularly critical to examine the importance of 
ongoing inflammation. One of the aims of this study was therefore to study markers of airway 
inflammation in relation to airway pathology in preterms and term-born control subjects.  
4.6 Long-term pulmonary outcome from premature birth 
Assessments of pulmonary function in premature children and adolescents will have to be an 
assessment of the therapeutic strategies of the past. Therefore, continually long-term 
surveillance and follow-up studies are required to identify positive trends as well as 
potentially untoward and iatrogenic consequences of neonatal intensive care medicine. To 
provide unbiased estimates of long-term outcome, complete cohorts of consecutive premature 
births, preferably representing entire geographic regions, should be followed into adulthood. 
Such optimal long-term follow-up studies are, however, demanding and challenging to carry 
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out. Consequently, the majority of published literature focuses on younger children (65;87;90-
95), studies tend to be hospital-based (96-98) rather than population-based (90;91;99) or they 
focus on particular subsets of preterms with prolonged oxygen dependency (96;100) or 
requirement for assisted ventilation (101). Birthweight as the sole criterion for inclusion 
(87;90;97;99;102;103) is practical, but assumptions regarding effects of prematurity per se or 
its treatment might be confused by small-for-date infants. Consequences of premature birth 
should be assessed in subjects who are included primarily on the basis of gestational age at 
birth and not on the basis of low birthweight. Thus, one of the aims of the present study was 
to provide descriptive data for respiratory health and pulmonary function in a complete 
regional cohort of survivors of extreme prematurity, approaching adulthood.  
 
Advances in perinatal care and neonatal intensive care medicine have altered the surviving 
preterm population through recruitment of more immature survivors at risk of long-term 
sequelae - but also reduced the potential for acute injuries. The combined long-term effect of 
this scenario is poorly described. To elucidate such effects, comparable regional birth cohorts 
from different eras of intensive care neonatology should be assessed by identical methods, 
preferably at the same age. However, the time span required makes this optimal strategy 
demanding. Concurrent assessment at different ages facilitates identical evaluation, but 
precipitates a discussion on growth effects. Summarising available knowledge on this issue, 
Eber and Zach (104) stated that hyperinflation may improve with growth whereas airway 
obstruction improve only slowly or not at all. Thus, with this knowledge at hand, another aim 
of the present study was to assess possible different patterns in lung function in children who 
were born extremely premature in the early 1980’s and in the early 1990’s. 
4.6.1 Measurements of pulmonary function in preterms  
Objective surveillance of long-term pulmonary outcome from premature birth through lung 
function testing rests on the notion that the data gathered are valid, i.e. accurate and precise 
measurements of the current status of the lung. Lung function testing requires extensive 
cooperation between the tested subject and the pulmonary technician. The tested subject must 
be able to hear and comprehend a complex series of instructions, and subsequently have the 
neuromuscular ability to comply with these instructions. Neurological and cognitive 
impairment is more common in preterms than in term-born children (105). In no published 
studies have the repeatability of complex lung function tests been assessed in preterms. There 
are thus reasons to examine to what extent preterms are capable of producing technically 
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adequate and repeatable lung function tests. Lung volume measurement in a whole body 
plethysmograph is a complex and a well suited model system, i.e., if successful, one may 
assume adequate performance also in simpler test situations, such as spirometry.  
4.6.2 Bias in sample selection 
Follow-up studies of premature children are influenced by the sampling process. Typically, 
hospital based samples from single, tertiary level, teaching hospitals have been studied instead 
of area based cohorts. Hospital based studies may include samples that are skewed with 
respect to adverse neonatal outcomes as well as risk factors for subsequent development of 
obstructive airway disease. These factors may bias any outcome measure. The recommended 
approach is to include consecutively born subjects from complete geographical regions (106). 
However, Escobar et al. found that only 13% of 111 studies on morbidity among surviving 
VLBW infants were population based (107). 
4.6.3 Infancy 
Respiratory morbidity is common in infancy, particularly in BPD survivors. Symptoms 
present as wheezing episodes, and readmission to hospital is common (108-115). Several 
studies of lung physiology in infants with a history of BPD have demonstrated decreases in 
forced expiratory flows and hyperinflation (68-72). Recurrent wheezing in preterms has been 
associated with greater expiratory flow limitation, (116;117) and ventilatory impairments in 
BPD survivors was related to the clinical severity of the BPD (69). 
4.6.4 Childhood, adolescence and adulthood 
In later childhood and adolescents, there may be a gradual decline to normal of wheezing 
episodes (92;97;118;119), although several studies report continual symptoms, particularly 
after BPD (87;91;120). Later in life, symptoms seem to improve further, even after severe 
classical BPD, while lung function abnormalities persist (96). Airway obstruction and 
hyperresponsiveness have been reported in a number of studies of schoolchildren and in a few 
studies of adolescents. In most studies, inclusion is based on birthweight, samples tend to be 
recruited from single tertiary centres and drop-out rates tend to be high. Many studies include 
only selected subgroups of preterms, such as only those with BPD (100) or only those who 
were ventilated in the neonatal period (101). In the few published population based studies, 
age tend to be low (91) and subjects with serious neonatal morbidity few (99). Some studies 
aspiring to describe outcome of premature birth include subjects born close to term (64;65). 
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4.6.5 Radiographic findings of the chest 
The initial chest radiographic appearances of most infants who are born extremely 
prematurely, are highly abnormal (121), particularly in those infants who go on to develop 
BPD (122;123). The definition of BPD has been linked  to abnormal chest x-rays since the 
condition was first described by Northway in 1967 (22;40;124). Attempts have also been 
made to relate the extent and the qualities of the pathology described on early chest x-rays to 
the subsequent risk of lung function abnormalities years later (125). In recent reports, 
however, the repeatability of chest radiographic interpretations have been questioned (122), 
and in a consensus conference in 2000, x-ray findings were not included in the definition of 
BPD (39). 
 
Subsequent to BPD in infancy, there is a gradual and slow improvement in the radiographic 
appearance (126-128). Several authors have noted that chest radiographs in later childhood 
may show only minor abnormalities, despite significant ventilatory dysfunction (96;126). The 
sensitivity of plain x-ray in diagnosing subtle lung pathology is limited, and indications for 
high-resolution computer tomography (HRCT) in children have increased (129). With its 
relatively low radiation dose, HRCT has been suggested as a useful method for follow-up of 
lung sequelae after premature birth (130). Few studies have presented such follow-up data. 
Oppenheim et al. (131) described radiological findings in all the 23 examined BPD survivors, 
born between 1974 and 1992. Their population was highly selected, however, as they were all 
requiring medical follow-up for pulmonary morbidity. Furthermore they were all fairly young 
(mean age 4 years) and the population was heterogeneous, with age ranging from two months 
to 13 years. In another study (132), the 26 subjects (aged 5-18 years) were all recruited due to 
status as pulmonary patients, as were the five participating subjects in a study of young adults 
(133). There is no information available in the literature, regarding findings from pulmonary 
HRCT performed in population-based, unselected cohorts of preterms. Thus, we have no 
knowledge on expected or typical findings in long-time survivors from premature birth who 
do not appear as pulmonary patients. 
 
Survival after extremely premature birth has increased over the past decades, parallel to 
profound advances in perinatal and neonatal care. The radiographic pulmonary findings in 
premature infants and in BPD have also changed during this time course, both in the neonatal 
period and in later childhood. The prominent findings of classic BPD have been replaced by 
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less impressive changes that apparently normalise during later childhood (127). The 
impression of radiological improvement, has been based on plain chest x-rays. A better 
understanding of these matters would require population based follow-up data, based on 
pulmonary HRCT in preterms born and treated in different eras of neonatology. Such 
assessments would require a reliable system for classification of pathological findings in a 
population of this kind. There is no available literature discussing relevant HRCT results in 
this kind of time perspective, and there is no published and validated classification system for 
relevant radiological findings. 
 
4.7 Summary of background information 
Over the past decades, the number of live-born extremely premature infants seems to have 
increased, and there has certainly been a marked increase in survival to discharge after 
neonatal intensive care treatment. These improved survival rates have been paralleled by 
profound advances in perinatal and neonatal care. As more vulnerable infants survive, the 
incidence of bronchopulmonary dysplasia (BPD) has probably also increased. The majority of 
extremely premature infants require extensive medical intervention, often paralleled by long 
periods of treatment with supplemental oxygen. Currently, BPD has been proposed the most 
common chronic lung disease in infancy. Thus, more immature infants are admitted alive into 
neonatal intensive care, and more of them survive after exposure to better – but also 
prolonged and more aggressive – treatment. Subsequent to premature birth and neonatal BPD, 
there are numerous reports of clinical asthma, airway obstruction, airway 
hyperresponsiveness, pulmonary hyperinflation and radiological findings in schoolchildren, 
adolescents and selected samples of adults. There is, however, little population-based 
information on these issues in current young adults born in the early era of neonatal intensive 
care medicine. Furthermore, no comparisons have been published between these pioneer 
subjects and comparable preterms exposed to more recent intensive care medicine. While 
inflammation is important in neonatal BPD, there is limited knowledge on the mechanisms 
underlying later respiratory manifestations. The importance and relevance of the family 
history of asthma and atopy, cigarette exposures, allergy and inflammation for long-term lung 
sequelae subsequent to BPD remains to be established. Principal determinants for airway 
obstruction and AHR in long-term BPD-survivors are not well described. Nevertheless, 
asthma-like symptoms in BPD-survivors are often treated with anti-asthma medication with 
potential for side effects. Most of the knowledge relating to lung sequelae from premature 
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birth is based on samples of subjects defined by their birthweight and born at tertiary level 
teaching hospitals. Objective surveillance of lung-function rests on the notion that the data 
gathered are precise and accurate measurements of the current status of the lung. Since 
premature birth is associated with various disabilities, there are reasons to question the 
feasibility and the precision of lung function testing in preterms. Published information on 
these issues is scanty.  
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5. Aims of the present study 
5.1 To assess the feasibility and precision of lung function testing in young people who 
were born extremely preterm, and in comparable subjects, born at term.  
5.2 To assess long-term pulmonary outcome after extremely premature birth in a 
population based cohort of young adults, born in the early 1980’s. 
5.3 To compare long-term pulmonary outcome subsequent to extremely premature birth in 
the early 1980’s and the early 1990’s. 
5.4 To characterise the lung disorder that occurs in young people who were born 
extremely preterm, and compare with subjects born at term. 
5.5 To establish knowledge regarding radiological findings on high resolution computer 
tomography (HRCT) of the lungs in young people born extremely preterm. 
 
6. Study design, subjects and methodology 
6.1 Study design 
The present thesis reports results from an observational follow-up study of two cohorts of 
subjects who were respectively exposed (preterms) and not exposed (term-born controls) to 
extreme premature birth. Preterms were matched individually 1:1 to term-born controls with 
respect to gender and time of birth, and otherwise unselected except that their birthweight was 
within 1SD of Norwegian mean. The preterms were defined after the event of interest had 
occurred, implying a historical design. However, antenatal, perinatal and neonatal data were 
recorded in the patient’s charts before outcome was assessed, and in this respect the design 
was historical and prospective. 
 
All subjects were seen twice within a period of approximately two weeks in 2001/2002 at the 
paediatric Cardio-Respiratory Laboratory at Haukeland University Hospital. On the first test-
day, the questionnaire from the International Study of Asthma and Allergy in Childhood 
(ISAAC) (134) and a specifically designed questionnaire were filled in by all subjects and 
their guardians. Subsequently, a full medical examination was done by one of two consultant 
pediatricians (TH or BTS). Spirometry with flow volume loops and whole body 
plethysmography were done on both test-days. Exercise testing and salbutamol 
responsiveness were assessed on the first test-day, while a methacholine provocation test was 
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done on the second. HRCT imaging of the lungs was done approximately within the two 
weeks used for lung function testing. To obtain adequate and comparable conditions for 
bronchial provocation, reversibility and allergy testing, subjects on medication were 
instructed to stop prior to testing as appropriate. Antihistamines were stopped one week 
before testing, long acting β2 agonists two days before while short acting β2 agonists and 
inhaled corticosteroids were stopped from at least 24 hours before testing. No subjects were 
on leukotriene blockers. No subjects were examined within two weeks of a respiratory tract 
infection or an asthma event. 
6.2 Ethics 
The Regional Ethics Committee approved the study. Informed written consent was obtained 
from participating subjects and their guardians. The study met the criteria listed by Emanuel 
et al. in their paper “What Makes Clinical Research Ethical” (135). Except venous punctures 
for blood sampling, no procedures were associated with discomfort or pain. All subjects were 
given the option to use local anaesthetic plasters (EMLA cream, AstraZeneca, Stockholm, 
Sweden). Except HRCT imaging, no procedures were considered to have potential for 
untoward negative consequences. The radiation dose was kept low by using modern 
equipment and limiting the number of slices. The radiation dose equivalent was estimated to 
0.5-1.0 milli Sievert (mSv) per examination. (For comparison, a standard antero-posterior 
chest x-ray is estimated to 0.02 mSv). The risk of developing cancers due to exposure to low 
level radiation was discussed by Mossman (136). Exposures below 100 mSv have not been 
associated with increased risks.  
6.3 Subjects 
6.3.1 The preterms 
The primary criterion for inclusion was gestational age (GA) less than or equal to 28 weeks at 
birth. In addition, children with birthweight (BW) equal to or below 1000 grams were 
included, irrespective of GA. All such infants who were born in the two periods January 1982 
through December 1985 (first birth-cohort) and February 1991 through June 1992 (second 
birth-cohort) were included, providing their mothers were residents of one of the two counties 
Hordaland or Sogn og Fjordane in Western Norway at the time of delivery. The first 
inclusion period was set to include survivors from an early era of intensive care neonatology, 
with access to good quality neonatal data, documented in standardised forms. The second 
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inclusion period was set to include pre-pubertal children at the age of ten (scheduled to be 
examined January 2002-June 2002), who were born in an era with access to modern 
equipment and treatment modalities, such as exogenous surfactant and perinatal use of 
corticosteroids. 
 
As the NICU at Haukeland University Hospital is the only unit in the region caring for sick 
premature neonates, the inclusion to the study was truly regional and population based. The 
regional population was approximately 500.000 and annual birth rates approximately 6700.  
Five preterms were outborn; the remaining 76 were inborn at the maternity unit at Haukeland 
University Hospital. NICU admission protocols were used to identify candidates for inclusion. 
To avoid dropouts due to misclassifications, charts were reviewed from all infants registered 
with BW below 1750 grams or GA below 32 weeks and in cases were information in the 
admission protocols were missing or unclear. A total of 346 charts were reviewed by two 
independent people: A registered nurse who had been working in the department for 10 years 
and this author. 
 
Eligible infants were considered included if admitted alive into the NICU. That is, changes in 
attitudes between the two periods, with respect to delivery suite resuscitation of infants at the 
threshold of viability, may have influenced the constitution of the included populations: In the 
1990’s, more immature infants may have been considered viable and live-born in the delivery 
suite, and thus admitted to the neonatal department, compared to the 1980’s (12). A possible 
sample bias of this kind may have increased the vulnerability of the preterms in the 1990 
birth-cohort. 
 
The GA set at admittance was reassessed with information from the obstetric and paediatric 
charts, i.e. copies of the pregnancy reports, ultrasound scans and paediatric assessment. An 
algorithm in accordance with Yudkin et al. (137) was employed when the neonates were 
originally admitted, and was also used in this retrospective reassessment. The number of 
completed weeks since the last menstrual period was compared to gestational age predicted by 
ultrasound scan performed before 21 weeks gestation and with postnatal assessment by 
paediatric examination according to Ballard (138). Scan assessment was preferred only if it 
differed more than two weeks from the estimate based on dates, whereas paediatric 
assessment was preferred if it differed four weeks or more from that based on dates or 
ultrasound scan. With nine of the 346 reviewed charts, the determination of gestational age at 
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birth was difficult, and the decision was left to an external expert on foetal medicine and 
intrauterine development. 
 
The restricted ranges for GA and BW applied in the process of inclusion were expected to 
restrict the statistical potential for these factors to predict variability in outcome measures. 
Effects from GA and BW on lung function outcome are apparent from other studies with 
wider inclusion criteria. In this study, however, the likelihood for these variables to predict 
outcome was expected to be low. 
 
Before the preterms and their guardians were asked to participate, the National Registry was 
consulted to ensure that they were alive. In order to achieve relevant knowledge on their 
medical status, local hospital registries and charts, and in special situations, also paediatric 
neurologists were consulted.  Severely disabled preterms were initially carefully approached 
through a telephone call from this author, orally requesting their willingness to participate. All 
others were approached through a standardised letter of invitation. There were 51 eligible 
subjects from the first cohort and 35 from the second. From the first cohort, two were 
inaccessible (one had moved abroad and one never responded), two refused to participate 
whereas one was excluded from the study due to severe Eisenmenger syndrome. All subjects 
from the second cohort responded positively.  
6.3.2 The term-born controls 
One individual control subject was selected for each included preterm. Birth protocols in the 
obstetric department were used to identify the temporally nearest term-born subjects of the 
same gender with birth weight between 3.0 and 4.0 kilograms, corresponding approximately 
to the cut offs for the Norwegian 10th and 90th centiles (139). If this subject refused to 
participate, the next was approached, and so on. As the control population should reflect the 
preterm population with respect to all relevant attributes except for gestational age at birth, a 
bias in its constitution would be a serious source of error. To ensure objectivity in the 
selection process, this was largely left to an uninvolved secretary with precise instructions. 
For financial and practical reasons, subjects with a home address implicating more than one 
hour transportation by car to the Haukeland University Hospital, were excluded. The socio-
demographics and the physical nature of the Bergen area, make it unlikely that this 
geographical constraint should introduce bias with respect to risk factors for obstructive 
airway disease. The only further criterion for exclusion was a registered diagnosis of a mental 
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or physical disability, likely to interfere with the test situations. Particularly, asthma was not a 
criterion for exclusion. There was only one exclusion due to these medical criteria; a young 
woman suffering from a serious lung condition for which she subsequently received a lung 
transplant one year later. 
 
The higher the number of subjects that had to be approached to recruit a voluntary control, the 
higher the likelihood of including subjects with a personal interest in being tested, introducing 
another possible bias. In this study, 61 (75%) of the primarily 81 invited control subjects 
responded positively. In cases of refusals, the next eligible subject was asked. To complete a 
full 1:1 matched control group, an average of 1.3 term-born subjects were approached for 
each included preterm. 
 
Socioeconomic disadvantage is associated with preterm delivery (140) and probably also with 
asthma (141). We chose not to match the control population for indicators of socioeconomic 
status. The educational level of the parents of the preterms and controls eventually 
participating in this study, revealed no significant differences. There was a non significant 
tendency for mothers of preterms to have stopped education after primary school compared to 
mothers of term-borns (22% versus 11%, p = 0.086), but no such trend for fathers. As 
socioeconomic status is more related to the educational level of the father (142), the 
likelihood for this type of selection bias in the control population was therefore considered to 
be low.  
6.4 Lung function tests 
Lung function was the main output measure of the study. The focus was on three aspects: 
Airway dimensions, airway reactivity and lung volumes. Standard, commercially available 
spirometric equipment was used, produced by SensorMedics inc., Yorba Linda, California, 
USA. The same experienced and certified (143) pulmonary technician performed all tests, 
blinded to the status of the test-person (preterm or control) and to any previous results. 
6.4.1 Maximum flow volume spirometry 
Gas flow was measured with a mass flow sensor incorporated in a Vmax 22 spirometer 
(SensorMedics inc., Yorba Linda, USA). Two probes, located in the centre of this device, are 
exposed to the gas stream. An electrical current cause them to heat-up. When particle velocity 
is present, it asymmetrically alters the temperature distribution around the two probes. 
 33
According to Kings Law, the cooling is proportional to the square root of the velocity. The 
temperature difference between the two sensors quantifies the particle velocity. A change of 
temperature of the probes, also leads to a change in resistance. The electrical current required 
to maintain a constant ratio of resistance in these differentially heated censors, is proportional 
to flow. When flow is measured directly, volume must be derived by integration of the flow 
information. The accuracy of the flow sensor is verified by the application of a precise and 
known volume of air over various flow rates. The American Thoracic Society (ATS) requires 
three different flow rates to cover the flows of interest. The flow sensor was thus calibrated 
with a 3 litre syringe at slow, medium and fast flow rates before each test. According to the 
specifications of the manufacturer, the equipment meets the ATS requirements for a 
diagnostic spirometer, i.e. an accuracy of at least ± 3% of readings or 50 ml, whichever is 
greater (144).  
 
Subjects were tested in the sitting position, wearing a nose clip. Two measurements were 
performed, one on each test day. For each measurement, recordings were repeated until at 
least three technically acceptable curves were obtained. Criteria for acceptability were that 
exhalation should start instantly and without hesitation, the peak expiratory flow rate should 
be clearly visible as a peak in the flow-volume loop and there should be no fluctuations. 
Expiration was considered terminated when a plateau in the volume-time curve was apparent. 
Criteria for reproducibility were in accordance with the ATS 1994 recommendations, i.e. the 
largest and second largest FVC and FEV1 should not differ more than 0.2 litres (144). In the 
final measurement report, the largest FVC and FEV1 from acceptable curves were recorded. 
The other maximal expiratory flow values were obtained from the single curve with the 
largest sum of FVC and FEV1. Most subjects were able to provide FVC and FEV1 with 
reproducibility well below 0.2 litres. The following spirometric variables were recorded: 
Forced vital capacity (FVC), peak expiratory flow (PEF), forced expiratory volume in first 
second (FEV1) and forced expiratory flow at 50% and 75% of FVC (FEF50 and FEF75). The 
mean values of the two final measurement reports from each of the two days were used in 
statistical analyses. 
6.4.2 Whole body plethysmography 
Lung volumes were determined with a combined pressure-flow plethysmograph, Vmax 
Autobox 6200 (SensorMedics inc., Yorba Linda, USA). This equipment function as a 
variable-pressure, constant-volume device while measuring the thoracic gas volume (Vtg) and 
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during quiet breathing, and as a flow plethysmograph during forced expiration. As biological 
controls, two reference subjects in the laboratory had their lung volumes measured monthly 
and the results logged and compared. Measurements were done in accordance with the 
guidelines of the European Respiratory Society (145). Calibration of the flow sensor and the 
plethysmograph (50 ml, frequency 2 Hz) was performed prior to each test in accordance with 
the automated procedures and the instructions given by the manufacturer (146). Test subjects 
were left outside during calibration and individual volume corrections of the plethysmograph 
were subsequently performed, based on body weight. A bacterial filter (MicroGard, 
SensorMedics inc., Yorba Linda, USA) with an attached mouthpiece was used. The added 
deadspace was included in the applied algorithms and dealt with by the software. Deadspace 
may have some influence on the measurements, as the temperature response to pressure 
changes within the deadspace and the lung may differ. Therefore, this volume was kept as low 
as possible. Subjects were tested seated in an upright position with the face pointing straight 
forward, supporting the cheeks in their hands, wearing a nose-clip. After closing the door and 
a period of relaxed tidal breathing to allow for thermal stabilisation and familiarisation with 
the situation, a baseline level of functional residual capacity (FRC) was established from at 
least four stable tidal breaths. Two techniques were used, the panting and the single 
inspiratory effort technique (147;148). With the panting technique, test subjects were coached 
to pant gently with a frequency of about 1 Hz (149). The shutter closed at the end of a tidal 
expiration (no flow) whereupon a series of at least four panting movements were done against 
it, recording the corresponding pressure-volume loops. After opening of the shutter, the test 
subjects made 2-3 tidal breaths before performing a full inspiratory manoeuvre to total lung 
capacity (TLC) followed by a full expiratory manoeuvre to the residual lung volume (RV). 
From each acceptable pressure-volume loop, a thoracic gas volume (Vtg) was estimated by 
applying the mathematical algorithms installed by the manufacturer (146). Subsequently, a 
mean Vtg was calculated. Pressure-volume loops were considered technically inadequate if 
the pressure gradient exceeded 1.5 kilopascal (kPa) or if there were obvious “looping” or open 
ends, nonlinear segments or other major irregularities. Cursor lines for slope calculations were 
adjusted only in cases of blunt mistakes (150;151). With the single inspiration technique, the 
breathing frequency was about 20 per minute. The shutter closed at the end of a tidal 
expiration (no flow), data collection was triggered to start at 0.25 kPa of inspiratory mouth 
pressure and the shutter was subsequently released when the pressure gradient had increased 
by another 0.25 kPa. Calculation of Vtg was based on pressure-volume plots recorded in the 
interval between 0.25 and 0.5 kPa. If the shutter closed at a lung volume that differed from the 
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established baseline level of FRC, the calculated Vtg was adjusted according to this volume 
discrepancy to obtain the correct volume of FRC. TLC was subsequently calculated by adding 
inspiratory capacity (IC) to FRC, and RV by subtracting the expiratory vital capacity (VC) 
from TLC (146;152). At least three test-manoeuvres were done and each final test-report was 
based on their average. The following lung volumes were recorded: FRC, TLC, RV and 
RV/TLC. In addition, airway resistance (Raw) was measured with the panting technique. 
 
The physical principle underlying the mathematical calculation of thoracic gas volume in a 
body plethysmograph is expressed in Boyle-Mariotte’s law. However, the algorithms finally 
installed in most commercially available equipment, have been subject to modifications based 
on certain assumptions that have been criticised (153;154). This applies particularly to the 
single inspiration technique if high pressures are generated against the shutter or if the 
manoeuvres are prolonged (154). With the equipment used in this study, influence from high 
pressure gradients and prolonged manoeuvres were avoided by calculating Vtg from pressure-
volume plots recorded in a narrow pressure interval between approximately 0.25 and 0.5 kPa. 
6.4.3 Test of airway hyperresponsiveness with methacholine chloride 
Airway responsiveness to methacholine was determined and expressed by the cumulative 
dose in µmol which caused a 20% decrease from baseline in FEV1 (PD20) (155). An 
automated, inhalation synchronized, dosimetric jet nebulizer, Spira Elektra 2 (Respiratory 
Care Centre, Hameenlinna, Finland) (156) with 2.0 bar driving pressure and an integrated 
turbine flow sensor, was used to nebulize methacholine. Nebulization-time was 0.5 seconds, 
set to begin after 100 ml of air had been inspired. Inspiratory flow was measured and should 
not exceed 0.5 litres/second. Two concentrations of methacholine were administered from 
separate dosimeters (2.5 and 25 mg/ml), calibrated to deliver 3.6 µl per 0.5 seconds. This set-
up ensured early to mid-inspiratory administration of a known volume of nebulized solution, 
inhaled with a controlled inspiratory flow rate. Methacholine was administered in doubling 
amounts, beginning with 0.045 µmol and – unless a positive response - ending at 22.3 µmol. 
Prior to administration of methacholine, a baseline FEV1 was determined after inhalation of 
saline 0.9 mg/ml. Subsequently FEV1 was measured one minute after each dose of 
methacholine. PD20 was calculated by interpolation between the doses immediately preceding 
and following the 20% fall in FEV1. 
Interpretation: The diagnostic sensitivity and specificity of the PD20 test is influenced by the 
different methods and equipment used, by the constitution of the population sample that is 
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tested as well as by the cut-off level set to define a positive response (157). A comparable 
control population is therefore imperative when AHR is to be assessed in a population 
subgroup with a particular exposure. In our laboratory, the cut-off value suggested by Godfrey 
et al. (158) work reasonably well in the routine diagnostic work, and was also employed in 
paper #1 and paper #2 of this study. The ratio between the maximum percent decline obtained 
in FEV1 over the maximum cumulative dose of methacholine (in µmol), was used as an index 
of the dose-response slope (DRS) (159). Thereby, a continuous index of AHR was obtained 
also in non-responders. DRS was used as an index of AHR in paper #3 and paper #4. 
6.4.4 Test of exercise induced asthma (EIA) 
EIA tests were performed within a setting of simultaneous measurement of gas exchange, 
oxygen consumption and exercise flow volume loops. The cardiopulmonary exercise data are 
not assessed as a part of this thesis. After establishment of a baseline FEV1, subjects were 
running to exhaustion on a treadmill (Woodway ELG 70, Weil am Rhein, Germany), wearing 
a face mask and connected to a Vmax 29 spirometer and cardiopulmonary exercise unit. To 
facilitate familiarization with the treadmill in children with potential for various disabilities 
(86), and to optimize the conditions for cardiopulmonary exercise testing, a modified Bruce 
protocol was used (160). The primary criterion for test-termination was exhaustion, with 
support from either a respiratory quotient (RQ) > 1.05, a heart rate > 95% of predicted 
maximum level (220-age in years), or a plateau in oxygen consumption. FEV1 was measured 
1, 3, 6 and 10 minutes after exercise was stopped (161;162). 
Interpretation: The EIA test was considered positive if the largest decline in FEV1 relative to 
baseline exceeded 12%.  
6.4.5 Test of reversibility to salbutamol 
After the last spirometry of the EIA test, 100 µgram salbutamol per 10 kg bodyweight was 
administered with a metered dose inhaler (Ventoline®) via a plastic spacer (Volumatic®). 
FEV1 was measured 10 minutes later. 
Interpretation: Reversibility to salbutamol was considered significant if the increase in FEV1 
relative to the baseline measurement obtained before the EIA test, exceeded 12%. 
6.5 High-resolution computed tomography (HRCT) of the lungs 
HRCT imaging of the lungs was performed with a General Electric Hi Speed Advantage 
Single-Slice Helical - CT scanner with 1.25 mm slice thickness; 0.5 second scan time, 120 
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kV, 50-100 mA, lung algorithm and 512-512 matrix. Approximately 10-12 scans in 
inspiration with 10 mm intervals were followed by 4-5 scans in expiration with 20 mm 
intervals. Total radiation exposure per examination was estimated to be 0.5 –1.0 mSv. All 
images were read at a PACS workstation with a window width of +1540 and window level of 
–400 Hounsfield units. Based on Bhalla scoring system for cystic fibrosis (163) and prior 
studies in BPD survivors, a scoring system consisting of 14 parameters was constructed. Four 
parameters of special interest were introduced in addition to those included by Bhalla: (1) 
small peripheral linear opacities, (2) triangular subpleural opacities, (3) mosaic perfusion, and 
(4) air trapping in expiration. The evaluation of disease extent was based on a geographic lung 
map with lung segment borders, in which all radiological findings were recorded. 
 
The examinations were read independently by two experienced paediatric radiologists. 
Observer one (SMA) read the HRCT images twice separated by a period of at least six 
months, while observer two (KRF) read the images once during May 2004. None of the 
observers had knowledge of previous results, clinical findings or lung function tests. Prior to 
the study, in order to standardise the scoring system, both observers analysed and discussed 
the findings of four different HRCT examinations (three patients with cystic fibrosis and one 
premature child who did not participate in this study).  
6.6 Assessment of allergic sensitization 
Skin prick tests against house dust mite (D. Farinae and D. Pteronyssinus), animal dander 
(cat, dog, horse), pollens (timothy, birch and mugwort) and moulds (Alternaria and 
Cladesporium) were done with standard extracts (Soluprick®SQ, ALK-Abello AS, 
Hørsholm, Denmark) in accordance with European guidelines (164). Histamine (10 mg/mL) 
and the allergen diluent were used as positive and negative control, respectively. A reaction 
was judged positive if mean of the two perpendicular weal diameters was at least 3.0 mm.  
6.7 Biochemical markers of airway inflammation 
Urinary and blood biochemical substances were measured to assess airway inflammation. 
Blood was drawn at the first test-day, whereas early morning urinary samples were brought on 
the second day. The urine was aliquoted and put to -80OC. To test stability of the substances, 
selected samples were left on the bench at room temperature and in the refrigerator for 1-5 
days, without significant impact on subsequent measurement results. Urinary creatinine was 
measured with Jaffes reaction, and urinary leukotriene E4 (U-LTE4) with ACE™ competitive 
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enzyme immunoassay (Cayman Chemical, Ann Arbor, USA) at the research laboratory in the 
Paediatric Department in Bergen. All U-LTE4 analyses were done in duplicate and expressed 
in ng/mmol creatinine. To measure urinary eosinophilic protein X (U-EPX), frozen urine was 
shipped on dry ice to the Pharmacia laboratory in Uppsala and analysed with a specific 
radioimmunoassay (Pharmacia, Uppsala, Sweden). U-EPX was expressed in µg/mmol 
creatinine. Serum eosinophilic cationic protein (S-ECP) was measured with Pharmacia CAP 
System ECP™ (Pharmacia Diagnostics AB, Uppsala, Sweden) at the routine laboratory for 
clinical biochemistry at Haukeland University Hospital in accordance with their routine 
protocols. S-ECP was expressed in µg/litre. Whole blood eosinophilic leukocytes (B-Eos) 
were counted (x109/litre) in a Bayer Technicon H3™ (Bayer, Leverkusen, Germany). 
 
In paper #4, we wished to examine if subjects in the preterm and the term-born population 
with “high levels” of these markers had increased methacholine responsiveness (High U-EPX, 
U-LTE4, S-ECP and B-Eos), and furthermore, if a potential association between “high levels” 
of these markers and methacholine responsiveness was different in the population born 
preterm compared to the population born at term. We defined “high levels” as values above 
the 75th. centile. The respective upper quartiles were defined by the values in the preterm and 
the term-born populations, separately. We could alternatively, have defined “high levels” 
from the complete data set or from control subjects only. Our control population was, 
however, not an optimal reference population. Furthermore, we had no way to predict in 
advance if the values of these markers would be similar in the preterm and the term-born 
population. Theoretically, increased or decreased levels of these substances could be related 
also to features other than airway inflammation. If quartiles were defined from the complete 
data set and a significant difference existed between the preterm and term-born population, 
this would influence sample selection differently in the two populations, and thereby 
potentially influence the results. Therefore, to us it seemed most correct to select subjects 
belonging to the upper quartiles based on cut-off levels established in the preterm and term-
born population, separately. 
6.8 Questionnaires 
Parents and participating subjects filled in three sets of questionnaires: A validated translated 
version of the Child Health Questionnaire (CHQ) (165) to assess quality of life, the 
questionnaire from the International Study on Asthma and Allergy in Childhood (ISAAC) to 
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assess airway symptoms, and a separate questionnaire designed to map remaining relevant 
demographic variables and health related information. 
6.9 Neonatal data 
Patient records were available for all but one preterm. For this single subject, relevant 
information was collected from discharge summaries and maternal recall. For all other 
subjects, information on neonatal variables was collected from the original paediatric records, 
mostly available in standardised forms that were filled in by the nurse on call with in situ 
responsibility for the care of the infant. Information on antenatal variables (maternal 
corticosteroids) was collected from the obstetric and paediatric records. 
6.10 Definitions of BPD, CLD and Asthma 
BPD was defined and classified in accordance with suggestions from the workshop on BPD 
in Bethesda, USA, arranged in 2000 by the National Institute of Child Health and Human 
Development/National Heart, Lung and Blood Institute/Office of Rare Diseases (39). A 
diagnosis of BPD was made in infants treated with oxygen for more than 28 days. BPD was 
defined as mild in infants breathing room air at 36 weeks PMA. The workshop suggests that 
infants requiring < 30% oxygen at 36 weeks PMA are classified as moderate BPD while those 
requiring ≥ 30% are classified as severe BPD. In order not to create subgroups that were too 
small, we chose to analyse all infants receiving oxygen treatment (any concentration) at 36 
weeks PMA together as moderate/severe BPD. 
CLD. The concept of CLD is often used to classify premature infants with requirement for 
oxygen treatment at 36 weeks PMA (41). In this study, CLD will correspond to 
moderate/severe BPD. 
Asthma. The main criterion for a diagnosis of asthma was at least one reported episode of 
wheeze within the preceding 12 months, reported in the ISAAC questionnaire. Not all 
subjects who report current wheeze have asthma. Therefore, we wished to confirm that 
reported symptoms were in fact expressions of a clinically relevant and current asthma. 
 
• In paper #1 and #2, asthma was defined by at least one episode of wheeze within the 
previous 12 months, and additionally, a confirmed airway hyperresponsiveness to 
methacholine (166). AHR was defined by a decline in FEV1 exceeding 20% relative to 
baseline before a cumulative dose of 6.7µmol methacholine had been administered (158). 
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• In paper #4, asthma was defined by at least one episode of wheeze within the previous 12 
months, and additionally, clinical support from either a current doctor’s diagnosis of 
asthma when the child was included to the study, or from a positive test for exercise 
induced asthma (EIA) or a significant reversibility to salbutamol.  
6.11 Statistical analyses 
The study was designed as a 1:1 matched controlled cohort study of two samples of subjects 
which differed with respect to gestational age at birth, but were otherwise similar. Tests 
devised to compare paired observations were therefore used to assess data that were available 
in a paired fashion. In univariate analyses, paired t-tests were used to compare group means, 
and McNemar’s test in cases of categorical data. A paired multivariate two way analyses of 
covariance was used to assess relationships between multiple explanatory variables and 
continuous numerical output-variables [the linear mixed model procedure of SPSS (167)]. 
Interaction terms (168) were constructed to assess potential effect-modifying influence in 
relation to outcome from a number of factors, e.g. being born in the first versus the second 
inclusion period, or having a history of non-BPD versus mild BPD versus moderate/severe 
BPD.  Paired odds ratios (OR) and confidence intervals (CI) were estimated according to 
Breslow & Day with special programming in Maple (169). 
 
In non-paired univariate group comparisons, two sample t-tests were used to compare group 
means and Pearson’s χ2- test in cases of categorical data. The homogeneity of the variances 
within compared groups was assessed with Levene’s test. Analysis of variance was applied to 
assess differences between non-paired groups, such as the BPD subgroups of the preterm 
population. Non-paired multivariate analyses were done with stepwise multiple linear 
regressions in order to explore relationships between potential explanatory variables and 
measures of outcome, such as lung function variables. Univariate trend analyses in continuous 
data were performed with linear regression if normally distributed and Kruskal-Wallis’ test if 
not, and with Pearson’s χ2- test for trend if data were categorical. 
 
Several outcome variables were asymmetrically distributed. Methacholine responsiveness 
represents a statistical challenge, as the variance in population-based studies is high and its 
distribution far from Gaussian. However, most researchers assume a lognormal distribution of 
the dose-response slope (159), as employed in the present study. Variables used to describe 
airway inflammation (B-Eos, S-ECP, U-LTE4 and U-EPX) were also asymmetrically 
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distributed, and we applied non-parametric statistical methods (Wilcoxon-Mann-Whitney) for 
group comparisons, in accordance with previous literature in this field (82). 
6.11.1 Statistical power 
The size of the study populations was defined in order to achieve a 90% power to detect a 
difference in FEV1 of at least 7.5% between preterms and matched control subjects in each of 
the two birth-cohorts and also between the two preterm birth-cohorts, providing a significance 
level (α) of 0.05 and 1 SD = 10% predicted. 
 
6.11.2 Particular statistical aspects relating to particular papers 
A. The study comparing two methods for lung volume assessment (paper #1) 
The approach suggested by Bland and Altman for method comparisons were used (170;171). 
The repeatability (precision) of each technique was determined by calculating the standard 
deviations (SD) of the differences between two replicate measurements. Agreement between 
the two techniques was assessed by calculating the SDs of the differences between paired 
measurements obtained with the two techniques. The SDs were used to calculate 95% limits 
of agreement between replicate measurements obtained with the same technique as well as 
95% limits of agreement between the two techniques. Repeatability of the techniques and the 
agreement between them were visualised by plotting the differences between paired 
measurements against their average values. Concordance between paired measurements was 
visualised by means of Kaplan-Meier plots (172). 
 
B. The study of HRCT findings in the lungs (paper #5) 
Agreement within and between observers regarding scores of radiological findings was 
visualised with Bland-Altman plots and examined with kappa (κ) statistic (170;171). 
Differences according to grading were tested with McNemar’s test of symmetry. Differences 
in score between subjects with and without BPD were assed the Mann-Whitney test. 
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7. Results and summary of papers 
7.1 Paper # 1 
Whole body plethysmography can by used to assess lung volumes in preterms. Despite 
somewhat inferior repeatability, preterms did not perform principally different from term-born 
control subjects (Table 1). By inference, this suggests that spirometry and flow volume loops 
can be used to assess airway function in preterms, since body plethysmography is a more 
complex procedure that partly entails adequately performed spirometry. When comparing 
repeatability for the two applied methods, the fraction of replicate measurements with 
discordance in the medium range was smaller with the panting than the single inspiratory 
effort technique. The fraction with a high discordance was comparable for both methods 
(Figure 1). The likelihood of making large mistakes thus seemed to be similar with both 
techniques. Therefore, if the standard panting method becomes technically too difficult, the 
single inspiratory effort method can be used in a clinical setting, but with more caution in 
research. 
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Table 1 
Repeatability of the panting and single inspiratory effort technique 
Panting Single inspiratory effort 
 
 
 
1SD * 
95% limits of 
agreement † 
1SD * 
95% limits of 
agreement † 
Non-asthmatic controls 0.16 20.3 0.18 23.1 
Non-asthmatic preterms 0.17 23.8 0.18 26.3 FRC 
All preterms 0.18 23.3 0.19 28.8 
Non-asthmatic controls 0.13 8.0 0.18 11.5 
Non-asthmatic preterms 0.19 12.9 0.18 12.2 TLC 
All preterms 0.21 12.5 0.18 12.4 
Non-asthmatic controls 0.14 39.5 0.23 66.7 
Non asthmatic preterms 0.20 60.0 0.23 72.2 RV 
All preterms 0.22 59.9 0.22 72.3 
 
 
* 1SD (litres) of the differences between two replicate measurements of the same lung 
volume, measured with the respective techniques. † 1.96 SDs of the differences between the 
two replicate measurements, reported as percentage of the means of the two measurements. 
Data are given for the ten year olds only, non-asthmatic controls (n = 33), non-asthmatic 
preterms (n = 25) and all preterm (n = 34). 
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Figure 1 
 
Assessment of lung volumes, method comparison 
 
 
Discordance between replicate measurements of FRC obtained with the panting and the single 
inspiratory effort technique in ten-year-old children. The x-axis represents the absolute 
difference between replicate measurements, and the y-axis represents the proportion of pairs 
with at least the observed difference. All the 69 tested ten-year-old subjects are included, i.e. 
preterms and term-born controls. 
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7.2 Paper # 2 
In 18 year old preterms born in the first inclusion period (1982-85), the prevalence of a 
doctor’s diagnosed asthma, regular use of asthma inhalers and recurrent wheeze was increased 
compared to term-born controls. Prematurity was associated with increased airway 
obstruction, resistance and hyperresponsiveness, as well as with pulmonary hyperinflation. 
Differences between preterms and term-born controls were mostly accounted for by subjects 
with a history of neonatal BPD, although small airway obstruction was markedly increased 
also in non-BPD subjects. Prolonged neonatal oxygen treatment significantly predicted 
current FEV1. Adjusted for height, gender and age, FEV1 was reduced with a mean of 580 
ml/second in subjects with a history of BPD, representing 1-2 decades of normal age related 
decline. 
 
 
 
7.3 Paper # 3 
Comparing preterms born in the 1980’s and in the 1990’s, the incidences of BPD and chronic 
lung disease (CLD) were similar. Compared to matched controls, current airway obstruction, 
AHR and pulmonary hyperinflation were similarly increased in the two preterm cohorts. 
Furthermore, current deficits in important lung function variables were similarly associated 
with the severity of neonatal respiratory disease in both cohorts (Table 2). Compared to 
matched controls, current FEV1 was reduced with respectively 18.6% and 18.7% of predicted 
in the two birth-cohorts in preterms who required supplemental oxygen at 36 weeks 
postmenstrual age. One-hundred days with neonatal oxygen supplementation predicted 
decreases in current FEV1 of 12%, and in current FEF50 of 25%, and these figures were 
similar in both birth-cohorts. With respect to subsequent small airway obstruction, the 
influence from a neonatal diagnosis of BPD seemed to have increased in the most recent 
birth-cohort (Table 2, test of interaction, p = 0.020). The impact on current FEF75 from the 
number of neonatal days with oxygen supplementation was non-significantly increased in the 
second birth-cohort compared to the first birth-cohort (test of interaction: p = 0.091), 
explaining 37% of the variability in FEF75 in the ten-year-olds (p < 0.001). Neither gestational 
age at birth nor birthweight was significant predictors of current lung function. 
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Table 2 
Paired decreases in lung function, by birth cohort and the extent of neonatal 
bronchopulmonary dysplasia (BPD) 
 
 
 
Extent of  BPD † 
 
 
p- values ‡ 
 
 
Birth 
cohort 
None or mild 
(n = 55) 
M/S 
(n = 24) 
Differences 
between 
birth-cohorts 
Influence 
from BPD 
91-92 5.5   18.7  
FEV1 
82-85 7.2  18.6 
0.901 0.762 
91-92 13.8 36.8 
FEF50 
82-85 18.7 40.3 
0.698 0.107 
91-92 12.1 41.6 
FEF75 
82-85 24.2 36.2 
0.566 0.020 
91-92 4.9 8.0 
FVC 
82-85 2.6 8.9 
0.650 0.388 
91-92 1.7 - 1.8 
TLC 
82-85 0.8 1.6 
0.818 0.184 
91-92 - 0.5 - 7.0 
RV/TLC 
82-85 - 0.8 - 6.4 
0.810 0.158 
91-92 -2.5 -28.9 
DRS * 
82-85 - 1.7 - 14.8 
0.134 0.996 
 
 
The figures are group mean differences between preterms and individually matched controls 
in percent of predicted, except for the variable * DRS (dose-response slope to methacholine) 
where differences between preterms and controls are given as median values. † The criteria for 
classification of BPD are given in the text. ‡ The p-values test "differences between the birth-
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cohorts” with respect to lung function outcome, and if the “influence from BPD” on 
subsequent lung function outcome differed between the birth-cohorts (interaction analyses). 
 
 
 
7.4 Paper # 4 
Asthma after premature birth was not significantly related to allergy or increased markers of 
airway inflammation. Increased AHR in preterms was not confined to those with asthma 
(Table 3). Furthermore, the substantially increased AHR in preterms was unrelated to 
inheritance, cigarette exposures, allergy and markers of airway inflammation. Instead, AHR 
was strongly and significantly related to a neonatal history of BPD and prolonged requirement 
for oxygen treatment (Figure 2). The urinary metabolite leukotriene E4 was increased in 
preterms compared to term-born controls. 
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Table 3 
Characteristics of current asthma in preterms and term-born control subjects 
 
 Preterms (n = 81) Controls (n = 81) 
 
Asthma 
(n = 22) 
Non Asthma 
(n = 59 ) 
p-value † 
Asthma 
(n = 10 ) 
Non Asthma 
(n = 71) 
p-value † 
DRS ‡ 
9.8 
(3.6, 26.6) 
6.2 
(3.7, 10.3) 
0.368 
12.6 
(4.7, 34.3) 
1.2 
(0.9, 1.7) 
< 0.001 
Allergy * 5 (22.7%) 5 (8.5%) 0.125 6 (60.0%) 6 (8.5%) < 0.001 
B-Eos 
0.130 
(0.064, 0.221) 
0.100 
(0.065, 0.164) 
0.259 
0.348 
(0.229, 0.501) 
0.121 
(0.084, 0.184) 
< 0.001 
S-ECP 
12.2 
(8.8, 18.1) 
10.7 
(6.9, 18.8) 
0.482 
17.1 
(12.8, 29.0) 
10.7 
(7.5, 19.6) 
0.071 
U-EPX 
34.4 
(27.6, 50.9) 
47.5 
(31.5, 86.5) 
0.131 
77.4 
(42.3, 95.6) 
37.1 
(24.7, 52.8) 
0.032 
U-LTE4 
40.2 
(23.0, 60.1) 
27.9 
(20.5, 48.2) 
0.322 
39.4 
(22.5, 51.2) 
23.2 
(15.3, 33.3) 
0.068 
 
Current asthma was principally defined by recent wheeze and a doctor’s diagnosis at study 
inclusion. * Number (%) in the respective groups with perennial allergies. † Relations between 
asthmatics and non-asthmatics in the preterm and term-born population, tested with χ2-test 
(Allergy), t-test (log10 DRS) or Mann-Whitney test. ‡ Dose response slop to methacholine, 
geometric means (95% CI). B-Eos = eosinophilic granulocytes (x109/litre), S-ECP = serum 
eosinophilic cationic protein (µg/l), U-EPX = urinary eosinophilic protein X (µg/mmol 
creatinine) and U-LTE4 = urinary leukotriene E4 (ng/mmol creatinine), all reported as median 
values (25-75 centiles).  
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Figure 2 
 
Methacholine responsiveness in the preterm and term-born populations 
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Methacholine responsiveness in young people born extremely preterm, classified by neonatal 
bronchopulmonary dysplasia, and in matched term-born control subjects. The x-axis 
represents the total cumulative dose of methacholine given to each subject, censored at the 
maximum administered dose of 22.3 µmol. The y-axis depicts the proportion of non-
responders at any given dose. In this graph, BPD was defined as neonatal requirement for 
supplemental oxygen ≥ 28 days. 
           Controls (n = 79) 
 
   
-------   Non-BPD (n = 19) 
 
 
…….   BPD (n = 55) 
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7.5 Paper # 5 
HRCT imaging of the lungs was successfully performed in 74 (91%) preterms. One subject 
was medically unable, and six did not show up. In two cases, images were printed on hard 
copies but accidentally not stored in the PACS system. Thus, images from 40 subjects of the 
first birth-cohort and 32 subjects of the second birth-cohort were assessed. The agreement 
within and between observers of a novel scoring system for radiological findings was 
moderate, but varied between different parameters. 
 
Radiological findings were revealed in 63 (88%) of the examined preterms. Total score was 
significantly reduced (i.e. less findings) in subjects of the second inclusion period (1991-92) 
compared to the first (1982-85). There was a tendency for higher scores in preterms with a 
history of BPD compared to those without, however, the differences did not reach statistical 
significance. There were no significant differences in scores between males and females, but 
maybe a weak tendency for lower total score in females (p = 0.10). Most of the described 
pathology was discrete linear or triangular opacities of unknown prognostic significance. 
Mosaic perfusion and air trapping observed in respectively 13% and 26% may, however, 
represent prognostic information. The significance of these findings as putative x-ray 
precursors of chronic lung damage can only be established through further follow-up of these 
young people, with concurrent lung function measurements and clinical surveillance. 
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8. Discussion 
 
Pulmonary sequelae after extremely premature birth were demonstrated in childhood and in 
early adult life. Adverse outcome at follow-up was strongly and significantly associated with 
neonatal respiratory morbidity. Subjects in both birth-cohorts with a neonatal history of BPD 
had similar, significant and substantial decreases in important lung function variables. In 18 
year old subjects with a history of BPD, the decrease in FEV1 corresponded to 1-2 decades of 
normal age related loss of lung function. Prolonged neonatal oxygen supplementation 
predicted current decreases in lung function, and for important lung function variables, this 
association was similar in the two birth-cohorts. Asthma and AHR in preterms were unrelated 
to markers of airway inflammation and to features usually observed with asthma, such as 
inheritance and cigarette exposures, and AHR was not confined to subjects with asthma. 
These findings suggest irreversible, structural damage to the airways and/or to the pulmonary 
interstitium as causal factors, rather than an ongoing, eosinophilic inflammatory disease. Less 
radiological findings in the second birth-cohort may reflect less structural damage in preterms 
born in the 1990’s. 
8.1 Methodological aspects  
8.1.1 The population sample 
The fundamental endpoint of clinical research is to develop generalizable knowledge. In order 
to achieve this, the population sample selected for a study should be representative and 
unbiased. 
 
Most studies that address the issue of long-term sequelae from premature birth, enrol subjects 
with low (102), very low (87;90;98;99;119) or extremely low (97;173) birthweight. Results 
from studies with this design may be influenced by subjects inappropriately grown for 
gestational age. Therefore, the principal inclusion criterion in the present study was 
gestational age. In order to include all preterms perceived as extreme, subjects with 
birthweight ≤ 1000 grams were also included, irrespective of gestational age. There were 
three of these growth retarded subjects in the first birth-cohort and four in the second. 
 
Population based studies are less likely to be influenced by known or unknown confounding 
factors compared to studies recruiting from tertiary level teaching hospitals, which is a 
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commonly employed design. Inclusion to the present study was truly population based since 
all mothers of the participating preterms were residents within a defined geographical area 
and, to the best of our knowledge, no preterm neonates born by mothers who were residents 
of this area, were referred to hospitals outside this area. 
 
In a number of published follow-up studies, the ratio between subjects actually examined 
versus the number of subjects eligible for inclusion, have been rather low 
(91;98;99;102;119;120;174;175) and in some studies, the tested fraction was in fact less than 
60% (98;99;119). High drop-out rates raise questions as to the representativeness of the 
sample that was eventually examined. In the present study, the drop-out rate was 6%. This is 
unusually low in population-based long-term follow-up, and comparable only to an Australian 
study (97). 
 
Bias due to selective or differential survival is difficult to exclude. The survival rate in the 
present study was 67%, similar to results reported for comparable populations in comparable 
institutions at the time (11). We have no reason to suspect that mortality in our institution was 
related to other factors or conditions than those operating in other comparable institutions. As 
was pointed out in a review (176), however, this issue can be answered only through full 
assessment of family background, antenatal exposures and neonatal data also for subjects not 
surviving. 
 
To conclude on this point, we hold the population sample examined in the present study to be 
representative and unbiased for long-term survivors after extremely preterm birth. 
8.1.2 Sample size, detection limits and statistical power 
The present study entailed assessment of a number of variables with different and partly 
unknown distributions, some of them far from Gaussian. Subgroups of various sizes were 
analysed. By nature, the issue of a priori sample size calculation becomes complex in a 
context of this kind. The study was powered to detect clinically relevant decreases in the 
preterm populations for the main outcome measure, which was FEV1. In order to directly 
address uncertainties relating to conclusions, confidence intervals were presented for most 
calculated mean values (177). The total number of subjects included was 162, of whom 81 
were born prematurely and 81 at term. As for a long-term clinical follow-up study in this 
field, this number is comparable to most previous reports. 
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In paper #3, we were not able to reject the null-hypotheses, as the two preterm birth-cohorts 
appeared strikingly similar with respect to FEV1%. This calls for a discussion over statistical 
power and detection limits. We had 90% power to detect a difference exceeding 7.5% for 
FEV1% between the two complete preterm birth-cohorts. Overlapping confidence intervals 
supported the notion of equality (177). Subgroup analyses according to neonatal BPD-status 
necessarily implied fewer subjects in each group, and therefore higher detection limits with 
respect to differences between them. We had, however, reasons to treat the BPD subgroups as 
ordinal groups. Therefore, the observed and striking similar trends in the two birth-cohorts 
with respect to outcome over increasing severity of neonatal BPD, supported the null-
hypothesis. Tests of interaction (168) gave further support, as a p-value close to 1.0 with 
respect to effect from birth cohort on subsequent FEV1%, made an effect unlikely. 
 
In paper #4, differences between relatively small subgroups were assessed (asthmatics versus 
non-asthmatics, smokers versus non-smokers, exposed versus unexposed to intrauterine 
cigarette smoking, subjects with a family history of asthma versus subjects without). In these 
circumstances, negative conclusions should be treated with caution. Again, confidence 
intervals were presented for all mean values, to address the issue of uncertainties (177). 
 
A larger population sample may have described these issues with greater certainty. However, 
large-scale, long-term, clinical studies of samples that are representative for young people 
with this particular neonatal background, are demanding to carry out. The issues of sample 
selection and sample size are complex and involves several difficult aspects (135;178-181). 
We regard the conclusions presented to be statistically adequately documented – even if the 
sample size by some may be perceived as marginal. 
8.1.3 Comparing pulmonary function in subjects of unequal age, height 
and gender 
In order to compare lung function in subjects of unequal gender, age and height, raw-data 
were transposed to percentages of predicted values, calculated by using recognised prediction 
equations. FEV1 was considered the main outcome variable, and “percent predicted” was 
calculated from a set of regression equations presented by Quanjer et al. (182). FEV1 was 
predicted rather well by these equations in control subjects, i.e. the FEV1 predicted was close 
to the FEV1 actually measured in subjects assumed to be healthy and normal, irrespective of 
 55
age, height and gender. Subsequently, most statistical comparisons were done within the 
paired framework of the study, i.e. by assessing paired differences between preterms and 
matched controls. In paper #3, we assessed outcome in 10-year-olds and 18 year-olds by 
comparison of paired differences between preterms and matched controls in the two birth-
cohorts. These differences were found to be basically similar for important lung function 
variables. Since the younger age group had approximately seven years of growth to reach the 
age of the older, this design precipitates a discussion of possible effects of growth: Lung 
function may develop differently with adolescent growth in preterms compared to subjects 
born at term. Summarising available knowledge on this issue, Eber and Zach (104) stated that 
hyperinflation may improve with growth whereas airway obstruction improve only slowly or 
not at all. We therefore consider the presented comparisons as valid despite the age 
difference, and we reckon the presented information on long-term trends as important.  
8.1.4 Classification of BPD in different time eras 
Oxygen is used both to diagnose and to treat BPD. Therefore, the strategies employed for 
weaning neonates from supplemental oxygen are important factors in the process of 
classifying neonatal respiratory morbidity. If oxygen supplementation is considered harmful, 
strategies for weaning from oxygen may also influence the extent of lung injury. One of the 
strengths of this study was that the senior medical staff was principally unchanged in the two 
inclusion periods. Despite new technology (pulse-oximetry), decisions regarding weaning 
from oxygen treatment were made with reference to the same clinical judgement (44). 
8.1.5 Test conditions 
The assessment of lung function at baseline conditions combined with two different tests for 
airway responsiveness and a reversibility test for salbutamol as well as measurement of gas 
exchange during exercise, created logistical challenges. The modified Bruce protocol 
employed in the exercise set-up, may underestimate the occurrence of exercise induced 
bronchoconstriction. The protocol was used for two reasons: We wished to combine 
assessment of exercise induced bronchoconstriction with measurement of gas exchange 
during exercise, for which purpose a ramp protocol with a rather careful start seemed better 
suited in this population of children. A standardized protocol with a careful start was 
anticipated to enhance the success rate in children who were unfamiliar with the test-situation 
and had a potential for various disabilities. 
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All subjects accepted the test situation and in no cases did we stop due to anxiety. All subjects 
were pushed rather hard for the last 4-5 minutes, and most subjects achieved a maximum 
heart rate above 95% expected. Mean (95% CI) RQ levels were 1.09 (1.08, 1.10). Mean 
maximum minute ventilation (95% CI) was 77% (74%, 79%) of the expected maximum 
minute ventilation that was calculated from FEV1×35. In accordance with previous literature 
(183), mean ventilatory reserves at maximum exercise tended to be less in preterms than in 
controls (21% versus 25%, respectively, p = 0.060). We are relatively confident, that the test 
conditions were acceptable also in the context of releasing a positive EIA response (161;162).  
8.2 Predictors of pulmonary outcome 
Neither BW nor GA at birth was significantly related to lung-function outcome. This was a 
consistent finding in univariate models as well as in multivariate models in combination with 
other neonatal potential explanatory variables. Clearly, pulmonary outcome from premature 
birth is related to these two variables (63;102;120). The mere fact that the preterms of the 
present study differed from term-born controls, supports this notion. In the present study, 
however, the distribution of these two variables - as defined by the inclusion criteria - was 
relatively narrow. Therefore, by nature, the design of the present study reduced the statistical 
potential for BW and GA to influence variability in outcome measures. Effects from short 
gestation and low BW on subsequent lung function, are more likely to be disclosed in studies 
with wider inclusion criteria (64;102;120). Much of the controversies (104) relating to which 
are the principal predictors for lung function outcome in subjects of premature birth (i.e. 
birthweight and gestational age versus neonatal conditions and treatment exposures), may be 
explained within the context of sample selection. Within the ranges given for BW and GA in 
the present study, neonatal respiratory morbidity (BPD and CLD) and prolonged oxygen 
supplementation were strongly and significantly associated with current lung function 
outcome. Prolonged neonatal requirements for oxygen treatment remained the principal 
predictive factor for current lung function outcome in multivariate models including other 
relevant neonatal variables. Inclusion of factors considered to be associated with asthma and 
airway hyperresponsiveness in unselected populations did not alter this picture. A trend seems 
to appear from the literature, indicating that BW and GA may be less associated with lung 
function outcome in studies with the more immature population samples. Our study fits well 
into this trend: The smaller the babies, the more susceptible they are to postnatal noxious 
exposures or conditions. The more mature the babies, the more robust they are to neonatal 
traumas, increasing the importance of factors such as BW and GA for outcome. This concept 
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is supported by a recent study on exercise capacity in ELBW children by Kilbride et al. (173). 
They examined a sample of children (9-15 years) born in the late 1980’s, selected by their 
capacity to complete an exercise test. There were no BW or GA differences between subjects 
with and without CLD (oxygen treatment ≥ 36 weeks PMA). This is certainly unusual. 
Nevertheless, lung function in ELBW subjects without CLD was close to normal, while 
ELBW subjects with CLD had highly significant airway obstruction. Hjalmarson & Sandberg 
(69) studied contemporary BPD infants at an age corresponding to term. There were no 
differences in BW (approximately 800 g) or GA (approximately 26 weeks) between infants 
classified as mild, moderate or severe BPD. Although abnormalities were found also in 
apparently healthy preterms and in mild BPD, those infants with the more severe BPD had the 
most pronounced functional abnormalities. GA was not related to outcome. This further 
supports the notion that neonatal respiratory morbidity is the principal predictor of long-term 
outcome in immature infants. It furthermore indicates that the relationship between prolonged 
requirements for oxygen and adverse lung function outcome is present also in survivors from 
contemporary neonatal intensive care. These data may represent an extension into this decade 
of the results presented in paper #3, showing that an extra day with oxygen treatment was 
related to similar decreases in lung function in preterms born the 1980’s and in 1990’s. There 
is evidence that airway obstruction in premature children track throughout childhood (104). If 
Hjalmarsons cohort follows the same pulmonary growth pattern, BPD survivors from this 
millennium, may also develop dysfunctional airways as described in paper #2, #3 and #4. 
Whether or not this is a noxious effect of oxygen per se is unknown and cannot be discerned 
from our study. Certainly, prolonged requirements for supplemental oxygen may represent the 
“final common output” of a series of events. A sequence of prenatal and/or postnatal 
predispositions, events or conditions may trigger lung injuries that bring about requirement 
for oxygen treatment that statistically becomes related to outcome, but with an uncertain 
causal relation. However, an independent noxious effect from oxygen is not biologically 
implausible. Both scenarios may be true, i.e. prolonged requirement for treatment with 
oxygen may be a marker of lung injury inflicted by other factors as well as an independent 
causal factor for additional lung injury. Whatever role oxygen supplementation may play in 
the lungs of immature infants, prolonged neonatal requirements seem to be a continued and 
well-suited prognostic indicator for subsequent long-term airway obstruction in this group of 
subjects. 
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8.3 Biological aspects of airway obstruction and 
hyperresponsiveness after BPD 
Limitation of maximal expiratory flow depends on the resistance of the airways and on the 
elastic recoil of the lung tissue (81;184). Therefore, one or both of these factors must differ 
between those who were born prematurely and those who were born at term. The major 
determinant for airway resistance is the cross sectional dimension of medium sized bronchi. 
The elastic recoil of the lungs depends to a large extent on the formation and adequate 
disposition of elastic fibres (185). Adequately formed three dimensional network of elastic 
fibres is also required for a normal alveolarization (186). The acute phases of RDS and BPD 
are characterized by a significant inflammatory response in the airway mucosa and in the 
interstitium of the lungs (54). Activated inflammatory cells release proinflammatory cytokines 
and various mediators as well as cytotoxic oxygen radicals and proteases, including elastase. 
Increased concentrations of free elastase and low α1-protease inhibitor activities have been 
detected in the airway secretion of some infants with BPD, and this imbalance has been 
suggested as a hallmark of lung injury of preterm infants (54). Altered elastic and fibrous 
networks is described in lungs after exposure to oxygen supplementation and positive 
pressure ventilation in preterm animals (77;187) and humans (52). Taken together, there is 
good evidence to suggest that the structure of the pulmonary interstitium may be affected by 
premature birth and/or associated oxygen toxicity, baro-traumas, infections and inflammatory 
responses. This mal-development of the pulmonary interstitium and of the acinar structures 
may alter peri-bronchiolar support with consequent alterations of elastic recoil and small 
airway resistance. The decreases in maximal expiratory flows observed in subjects of 
premature birth in the present study may be explained within this conceptual framework. 
Jacob et al. (100) studied pulmonary pressure-volume curves of 11 year old children who 
were born at 24-31 weeks PMA and required oxygen treatment to at least one month after 
term. They reported reduced elastic recoil pressure at 90% TLC (78% predicted ± 26%), 
however with a relatively wide scatter. Their overall findings were mixed and seemingly 
contradictory, but consistent with coexistence of emphysematous changes as well as with 
fibrosis. No studies have supplied evidence that inhaled steroids improve the airway 
obstruction occurring after premature birth (89;188). Thus, there is a relatively consistent line 
of arguments from basic science to clinical studies supporting the notion that airway 
obstruction subsequent to premature birth represents structural pulmonary sequelae, probably 
related to altered interstitial elastic and/or fibrous networks. The observations of the present 
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study fits well into this picture: Airway obstruction in preterms was strongly related to the 
neonatal respiratory morbidity and we were unable to demonstrate any association between 
airway obstruction and the examined markers of airway inflammation (paper #4). The 
association between neonatal respiratory morbidity and outcome seemed to be quantitatively 
similar in preterms born in the early 1980’s and the early 1990’s (paper #3). 
 
AHR is observed in most BPD-survivors (104). In asthma, AHR is often taken as evidence of 
poor inflammatory control (189;190), leading to suggestions of increased treatment intensity. 
In preterms of the present study, no relation was observed between AHR and markers of 
airway inflammation, nor was there any association between a diagnosis of asthma and 
markers of airway inflammation (paper #4). AHR was, however strongly related to neonatal 
respiratory morbidity and prolonged requirement for supplemental oxygen. Some, but not all, 
of this effect was mediated through an association between AHR and FEV1%. 
 
The capacity of isolated airway smooth muscle to shorten in response to a maximal 
cholinergic stimulus is greater than its shortening capacity in vivo in response to a 
corresponding stimulus (191). In vivo, the maximal response to methacholine is attenuated by 
increasing the lung volume at which bronchoconstriction is measured (192). On the bases of 
these experiments, it has been suggested that the limit to airway smooth muscle shortening in 
vivo is related to the elastic load that the lung parenchyma imposes on the airway smooth 
muscle when it contracts (192). In line with this, loss of elastic recoil should induce increased 
responsiveness to methacholine. Bellofiore et al. (80) treated rat lungs with elastase and found 
an increase in lung volumes, reduced lung elastic recoil, diffuse parenchymal lung destruction 
and loss of alveolar attachments to the airway walls. Concurrent with these changes there was 
an increase in the maximal degree of airway narrowing to inhaled methacholine. These 
experiments provide support to the notion that AHR after premature birth is not an expression 
of airway mucosal inflammation, but of pulmonary parenchymal structural sequelae and 
possibly of distorted elastic and/or fibrous architecture of the interstitium. Structural factors 
influencing airway narrowing during testing for AHR was recently reviewed by Brusasco & 
Pellegrino (193). The data provided through the present thesis fits nicely into this theory: 
Airway obstruction as well as AHR was strongly related to neonatal respiratory morbidity and 
not associated with current markers of inflammation or features generally associated with 
childhood asthma (paper #4). 
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8.4 Future prospects for pulmonary function in children of 
premature birth 
FEV1 follows a well-described track throughout a lifespan. Subsequent to childhood growth, a 
stable plateau phase is followed by a decline throughout adulthood (194). The maximum level 
of FEV1 obtained, as well as the timing of onset and subsequent rate of decline in adulthood, 
determine when and if lung function impairment will occur. Thus, the deficit in FEV1 
described for subjects with BPD in paper #2 of this study, represents more than a decade of 
normal age related decline. Furthermore, the rate of decline in lung function in adulthood 
differs between population subgroups (194). Cigarette smoking, childhood pneumonias 
(195;195), asthma (196) and AHR (197) may accelerate the normal aging process of the lung. 
Our preterm population smoked cigarettes at the same rate as their controls, had experienced 
more childhood pneumonias, used more asthma inhalers and had a distinctly increased 
prevalence of AHR. A prospect of an accelerated decline in lung function in adulthood is 
therefore possible. 
 
Shaheen et al. (195) showed us that relatively minor insults to the lungs of small children may 
be associated with chronic obstructive airway disease (COPD) at the other end of life. The 
lungs of extremely premature children are definitely not exposed to minor insults but to major 
traumas. There is furthermore a coherent line of evidence that these traumas may lead to 
structural injuries, leaving little prospects of improvement. Already in 1990, in an editorial in 
the New England Journal of Medicine, Mary Ellen Wohl (198) expressed her worries for the 
pulmonary future of BPD patients. Hack and Fanaroff  (11) expressed similar worries one 
decade later. Today, in 2005, these concerns still seem relevant.  
8.5 Implications for contemporary BPD survivors 
We found a similar relation between the extent of neonatal BPD and current lung function in 
two comparable cohorts of preterms, born in the 1980’s and the 1990’s. Hjalmarson and 
Sandberg showed us that infants born in this decade, requiring oxygen treatment at 36 weeks 
PMA, had lung function abnormalities that partly were related to the extent of neonatal BPD. 
One may therefore speculate that BPD survivors of contemporary neonatal intensive care 
medicine will also grow up with lung sequelae, particularly those with prolonged 
requirements for oxygen treatment.  Development of bronchi precedes development of acini, 
starting with primary septation approximately at 25-26 weeks PMA. Thus, in the most 
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immature BPD-survivors of today, acinar development takes place solely after birth. These 
infants therefore, are at risk of suffering from more acinar and interstitial injury than previous 
BPD-survivors. These facts call for careful follow-up studies. 
9. Concluding remarks and implications 
The studies of this thesis showed that: 
• Lung function testing could be conducted by preterms with a precision that did not differ 
significantly from term-born control subjects. 
• Pulmonary sequelae from extremely preterm birth persisted into early adulthood. 
• Pulmonary sequelae in subjects born extremely preterm in the early 1980’s and in the 
early 1990’s were of similar magnitudes, and also similarly related to prolonged 
requirements for supplemental oxygen. 
• Asthma and AHR subsequent to extremely preterm birth differed from typical childhood 
asthma with respect to important features. Current AHR was best explained by neonatal 
variables. 
• High-resolution CT revealed radiological findings in 81% of preterms born in the 1990’s 
and in 93% of preterms born in the 1980’s. Relatively minor abnormalities, such as linear, 
triangular, and subpleural opacities, were the most prevalent findings. 
 
It is only recently that the first large cohorts of survivors from extremely premature birth   
have reached adulthood. In a life-time perspective, their pulmonary prognosis is unknown. In 
this context, therefore, extreme neonatal intensive care medicine is experimental medicine. 
Certainly, survival has increased and morbidity is reduced also in infants born at later 
gestation. A shift in the neonatal clinical course may have occurred, with relatively eventfree 
survival of infants previously exposed to harsh interventions, paralleled by recruitment of a 
new category immature survivors that previously died. The proportion of these infants 
requiring supplemental oxygen at 36 weeks PMA seem to have settled at approximately 1/3. 
Particularly for these subjects, there is reason for concern regarding life-long pulmonary 
prospects. As survival of these infants has become the rule rather than the exception, their 
absolute number is rising and their public health importance is increasing. Without medical 
interference, most of them would have died. Appreciating this scenario, an obligation for 
proper follow up, treatment and guidance fall upon the health profession that facilitated their 
survival. 
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